<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty percent of patients with the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, frequently following treatment by radiation or chemotherapy, have prognostically unfavorable deletions of the long arms of chromosomes 5 and 7, or <z:mp ids='MP_0004027'>trisomy</z:mp> 8, as have the 25% of patients with <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> where remissions last 6-12 months, and where relapse cannot be prevented </plain></SENT>
<SENT sid="1" pm="."><plain>In contrast, patients with prognostically favorable cytogenetics (translocation 15; 17 or 8; 21 or inversion 16) maintenance chemotherapy may prevent relapses </plain></SENT>
<SENT sid="2" pm="."><plain>Of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients, 85% can achieve hematological remission with interferon alpha, and 40% a partial cytogenetic remission, which probably delays relapse </plain></SENT>
</text></document>